Xenon Pharmaceuticals Inc (XENE) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $441.0M

XENE ranks #2000 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

318 institutions disclose a position in XENE, but none treat it as a major bet — even Affinity Asset Advisors, LLC, its most concentrated holder, allocates just 4.3% of its own portfolio to it.

XENE is down 2.4% today, but institutions show net buying of $441.0M this quarter — a divergence between today's price move and the underlying institutional flow.

XENE reported a net loss of $409.2M over the trailing twelve months.

• Not yet profitable — net loss of $409.2M over the trailing twelve months
• Revenue declined 82.8% year over year
• Net income declined year over year, from -$278.2M to -$409.2M
• Operating cash flow was negative, using $279.1M in cash
• Current ratio of 13.42x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range